Target Audience
This activity has been designed to meet the educational needs of primary care physicians, general practice, internal medicine, and nurse practitioners involved in the care of patients with diabetes.

Statement of Need/Program Overview
Cardiovascular disease continues to be the leading cause of death among men and women in the United States. The emphasis on evaluating and treating cardiovascular disease has changed from the traditional model to a global evaluation encompassing multiple risk factors, such as hypertension, diabetes, obesity, and dyslipidemia. Increased awareness and familiarity with a number of diverse areas is required. Diabetes, being one of the strongest risk factors, continues to grow at a rapid rate. Therefore, it is necessary to educate clinicians not only on the new data but on how the data can be applied to improve patient care.

Hypertension Control: Getting to Goal
Educational Objectives

• Describe evidence that treating diabetes and metabolic disorders can help prevent CVD events
• Choose strategies for achieving blood pressure goals in patients with diabetes
• Explain microalbuminuria as a treatment target for prevention of nephropathy and CVD
• Describe the relationship of specific antihypertensive and glucose-lowering agents to congestive heart failure.

Managing Dyslipidemia and the Prevention of Macrovascular Disease
Educational Objectives

• Describe the pathophysiology of dyslipidemia in the patient with diabetes
• Identify dyslipidemia as a major preventable risk factor for CVD and diabetes
• Choose strategies for aggressive combination therapy of dyslipidemia in diabetes
• Recall the relationship of glucose-lowering agents to dyslipidemia and CVD risk

Faculty
Eliot A. Brinton, MD
Director, Metabolism Section
Cardiovascular Genetics
Associate Professor
University of Utah
School of Medicine
Salt Lake City, Utah

Ronald F. Goldberg, MD
Professor of Medicine at University of Miami
Miller School of Medicine
Miami, Florida

Domenic A. Sica, MD
Professor of Medicine and Pharmacology
Chairman, Division of Clinical Pharmacology
and Hypertension
Medical College of Virginia,
Virginia Commonwealth University
Richmond, Virginia

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™ for each podcast. Physicians should only claim credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter	Reported Financial Relationship
Eliot A. Brinton, MD	Consulting Fees: Abbott, KOS, Merck Speakers Bureaus: Abbott, KOS, Merck, Pfizer, Takeda, Wyeth Contracted Research: Merck, Pfizer, Takeda
Ronald F. Goldberg, MD	Speakers Bureaus: Lilly/Takeda, Pfizer, Merck, Schering Plough, KOS, Astra Zeneca, Abbott Contracted Research: Novo/Nordisk, Pfizer, Merck, KOS, Astra Zeneca, Daiichi-Sankyo Consulting Fees: Lilly/Takeda, Pfizer, Merck, Schering Plough, Astra Zeneca, Abbott
Domenic Sica, MD	Consulting Fees: King Pharmaceuticals

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager	Reported Financial Relationship
PIM Clinical Reviewers: Jan Hixon, RN; Trace Hutchison, PharmD; and Linda Graham, RN	Have no real or apparent conflicts of interest to report.
Bart J. Zoni	Has no real or apparent conflicts of interest to report.
Patrick Crowley	Has no real or apparent conflicts of interest to report.

Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period October 2007 through October 2008, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine. 

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks.


Media
Internet


Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation (CMH), Educational Concepts in Medicine (ECM), and Takeda Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CMH, ECM, and Takeda Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.